Background {#Sec1}
==========

Head and neck cancer encompasses a large number of tumor entities originating from subsites such as the nasal cavity, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx and salivary glands. The majority of these tumors are squamous cell carcinoma \[[@CR1]\]. Head and neck cancer is the fifth most common cancer worldwide. In the United States about 55,070 new cases were estimated for the year 2014 \[[@CR2]\].

Approximately 60 to 80% of patients present with locoregionally advanced disease at time of diagnosis. Concurrent radiation therapy (RT) and chemotherapy has become the standard of care for this subset of patients \[[@CR3], [@CR4]\]. Overall survival after chemo-radiotherapy (CRT) ranges between 50 and 60% after 5 year of follow up. Local and/or regional recurrence is the most frequent form of therapy failure after CRT, while failure due to metastasis is much less common \[[@CR5]--[@CR7]\]. Close follow-up of the neck after CRT in this patient group is therefore very important. There is a wide variability regarding the decision for salvage neck dissection as well as post-treatment surveillance imaging.

The aim of this retrospective study is to investigate whether the initial location of the pathological lymph nodes and size changes after treatment evaluated using CT studies, in patients diagnosed with a locoregionally advanced invasive head and neck squamous cell carcinoma, can help predict outcome and can help us in selecting patients who might benefit from a closer follow-up with more frequent radiological examinations.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between January 2002 and December 2012, 539 patients with invasive head and neck squamous cell carcinoma were treated with (C)RT at our centre. After the exclusion of patients with in situ cancer, metastasized disease or N0 disease at time of diagnosis, unknown primary tumors, nasopharyngeal or sinonasal primaries, RT at another centre and neoadjuvant chemotherapy or upfront surgery before RT, we had a cohort of 183 patients for further analysis. Of these patients 183 patients, 168 had a CT evaluation 4 months following the end of treatment.

All patients received external beam radiotherapy and were CT planned. The primary tumor and pathological lymph nodes were irradiated to doses ranging from 69.96 to 72 Gy. Mean overall treatment time was 43.4 days (range, 37-58 days). Most patients received concurrent cisplatin. A smaller group was treated with cetuximab or carboplatin/5-fluoro-uracil, or was included in a clinical trial and received alternative or additional therapeutic regimens. Patient and treatment characteristics are presented into more detail in Table [1](#Tab1){ref-type="table"}. For all patients with oropharyngeal tumors, formalin-fixed, paraffin-embedded tissue was centralized (University Hospital of Leuven) for Human papilloma virus (HPV)-status determination. HPV testing was performed using a previously validated algorithm using p16 immunohistochemistry followed by HPV-polymerase chain reaction (PCR). A tumor was regarded as HPV related when both p16 immunohistochemistry as well as HPV-PCR were positive. For p16 immunohistochemistry a purified mouse anti-human p16 antibody (G175-405, BD Pharmigen) was used. Sections were scored as p16 positive when clear p16 immunoreactivity was seen in at least 50% of cells.Table 1Patient and Treatment CharacteristicsCharacteristicNo. of patients (*n* = 183)%Mean age (y)59Sex Male15585Primary tumor site Oral cavity3016 Oropharynx\
 HPV +\
 HPV --\
 Unknown HPV status122\
20\
92\
1067 Hypopharynx2514 Larynx63T classification^a^ T184 T24726 T35128 T47642N classification 13217 214278 2a74 2b6334 2c7239 395Radiation therapy 3D CRT8446 IMRT9954Systemic therapy none3519 cisplatin11864 carboplatin/5-FU21 cetuximab116 panitumumab84 cisplatin + tirapazamine84 cisplatin + zalutumumab11*Abbreviations*: *3D CRT* three-dimensional conformal radiation therapy, *IMRT* intensity-modulated radiation therapy, *5-FU* 5-fluoro-uracil, *HPV* Human papilloma virus. ^a^1 patient had 4 synchronous head and neck malignancies and was not included in the T-classification statistics

CT studies were carried out before treatment and 4 months after the completion of treatment. If the CT scan was negative at 4 months, further follow-up was done by clinical examination. PET-CT examination was not routinely performed in the patients.

Analysis of the CT imaging data {#Sec4}
-------------------------------

CT-scans prior and following CRT were reviewed for all included patients. All CT studies were performed using multidetector spiral CT. An iodinated contrast agent was injected in most patients; 100 ml at a rate of 1-1.5 ml/s. Scanning was started 80-100 s after the start of the contrast agent injection. The native CT-images were acquired with a slice thickness of 0.6-0.75 mm, and reformatted for display with a slice thickness of 3 mm.

To obtain volumes and diameters of the lymph nodes, every lymph node was contoured on each slide. Consecutively, volumes and diameters were calculated using the Impax Volume Viewing 3D software from Agfa Healthcare. At patient level volumes were obtained by considering the sum of all pathological lymph nodes volumes in one patient. At nodal level individual pathological lymph nodes volumes were used. Lymph node levels were clustered (level I-III, IV-V and VI-VII) and compared pairwise. Furthermore, necrosis, calcifications and ECS was evaluated on all the CT studies. CT criteria for ECS were apparent fat and soft tissue infiltration or infiltration of sternocleidomastoid muscle, internal jugular vein or carotid artery.

All CT scans were analyzed by a single observer (a professor in radiology specialized in head and neck imaging) concerning the presence of pathological lymph nodes, the level of the lymph nodes, and the presence of extracapsular spread or necrosis. The volume and diameter of the lymph nodes were measured by a resident in radiation oncology under the supervision of a radiologist and radiation oncologist specialized in head and neck cancer.

Statistical analysis {#Sec5}
--------------------

Description of the time-to-event outcome (LC (local control), RC (regional control), MFS (metastasis free survival), DFS (disease free survival), OS (overall survival)) of the patient cohort was based on Kaplan-Meier estimates. The predictive power of localization and volume changes were analyzed by Cox regression models, and results presented as hazard ratios (HR) with 95% confidence intervals. Predictors for binary outcome were analyzed by logistic regression models, and results presented as odds ratios (OR) with 95% confidence intervals. Furthermore, a multivariate analysis was done to correct for T stage, N stage, pre-RT diameter, the presence of necrosis or calcifications within the pathological lymph nodes, HPV and ECS.

Analyses at lymph node-level were based on generalized estimating equations (GEE) to account for clustering of lymph nodes within patients. Size changes of pathological lymph nodes are presented as percentage of change. A negative % indicates decrease, a positive % increase. Disappearing pathological lymph nodes after treatment were considered as a 100% decrease of volume and diameter. Analyses have been performed using SAS software (version 9.4 of the SAS System for Windows).

Volume change was analyzed at patient level as well at individual nodal level. Data at patient level were correlated with RC, MFS, DFS and OS, with inclusion of disappearing pathological lymph nodes (100% decrease of volume) after treatment. At individual nodal level data were correlated with individual lymph node relapse (LNR), and analyzed both with in- and exclusion of disappearing pathological lymph nodes.

Change of largest axial diameter was analyzed on individual nodal level only, both with and without disappearing pathological lymph nodes after treatment.

Results {#Sec6}
=======

Survival, disease control, CT characteristics {#Sec7}
---------------------------------------------

We report the following 2-year outcome rates: LC 86% (95% Confidence Interval: 80-90%), RC 83% (95% Confidence Interval: 77-88%), MFS 77% (95% Confidence Interval: 70-83%), DFS 65% (95% Confidence Interval: 57-71%) and OS 70% (95% Confidence Interval: 63-77%). Median observed follow-up was 5.04 years (Q1 3.48 years; Q3 7.04 years). For 116 patients we had at least 2 years of follow-up.

The pre- and post-CT study characteristics are presented in Table [2 a and b](#Tab2){ref-type="table"}.Table 2CT parameters on pre and post RT CT studyVariableStatisticAlla.Sum-volume*N*183Mean18.4Std31.21Median9.7IQR(3.9; 19.9)Range(0.3; 257.3)Largest diameter*N*183Mean26.0Std14.46Median23.0IQR(17.0; 32.8)Range(2.6; 123.0)ECS Non/N (%)146/183 (79.78%) Yesn/N (%)37/183 (20.22%)Necrosis Non/N (%)60/183 (32.79%) Yesn/N (%)123/183 (67.21%)Calcifications Non/N (%)180/183 (98.36%) Yesn/N (%)3/183 (1.64%)b.Sum-volume*N*168Mean3.8Std8.02Median1.3IQR(0.7; 3.1)Range(0.1; 56.7)Largest diameter*N*168Mean15.2Std9.19Median12.5IQR(9.6; 16.8)Range(5.5; 55.8)ECS Non/N (%)150/168 (89.29%) Yesn/N (%)18/168 (10.71%)Necrosis Non/N (%)115/168 (68.45%) Yesn/N (%)53/168 (31.55%)Calcifications Non/N (%)147/168 (87.50%) Yesn/N (%)21/168 (12.50%)

Location {#Sec8}
--------

The distribution of affected lymph node levels in our patient cohort is presented in Fig. [1](#Fig1){ref-type="fig"}. Level II was most frequently affected. Regarding the risk for distant metastasis, a significant influence was seen for the location of the pathological lymph nodes. The metastatic risk increases when levels IV-V are affected rather than levels I-III. A similar observation is seen for levels VI-VII (Table [3](#Tab3){ref-type="table"}). On the other hand, no significant differences were found for RC or DFS.Fig. 1Distribution of affected lymph node levels Table 3Impact of PLN localization on metastatic riskLevelsLevelsHazard ratio (95% CI)*p*-value\
univariate analysis*p*-value multivariate analysis^a^I-IIIIV-V0.325 (0.165;0.639)0.00110.0002IV-VVI-VII0.461 (0.127;0.745)0.08520.0302Hazard Ratio \<1 (\>1) means lower (higher) risk for lower levels*Abbreviations*: *CI* confidence interval, *PLN* pathological lymph node. ^a^Corrected for T stage, N stage, pre-radiotherapy diameter, necrosis, calcifications, extra-capsular spread and HPV

Size change {#Sec9}
-----------

### Volume {#Sec10}

At a patient level, following multivariate analysis, less decrease of total lymph node volume on a CT study was significantly associated with a higher risk for regional relapse (OR 1.039, *p* = 0.003), distant metastasis (HR 1.006, *p* = 0.0277) and poorer DFS (HR 1.01, *p* = \<0.001) and OS (HR 1.006, *p* = 0.0037). At nodal level, less decrease of volume of an individual lymph node was associated with a higher risk for LNR, both with in- (OR 1.015, *p* = 0.0126) and exclusion (OR 1.009, *p* = 0.033) of completely resoluting pathological lymph nodes.

### Largest axial diameter {#Sec11}

Less decrease of largest axial diameter or an increase of diameter was correlated with a higher risk for LNR. Both with and without considering completely resoluting pathological lymph nodes, a nonlinear trend was observed for this relation (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Hence, the OR associated with a 1% increase in diameter around the median value was conducted (Table [4](#Tab4){ref-type="table"}).Fig. 2Nonlinear trend of diameter change in relation with risk of Lymph Node Relapse (LN Relapse) with inclusion of completely responding LN's. The *dots* represent predictions for individual LN's Fig. 3Nonlinear trend of diameter change of diameter change in relation with risk of Lymph Node Relapse (LN Relapse) with exclusion of completely responding LN's. The *dots* represent predictions for individual LN's Table 4Predictive value of diameter change for lymph node relapseDmaxOdds ratio (95% CI)*p*-value\*with CR PLNΔDmax (nonlinear trend)\<0.001ΔDmax (+1% \~ median)1.012 (1.006;1.017)\<0.001without CR PLNΔDmax (nonlinear trend)0.0167ΔDmax (+1% \~ median)1.009 (1.003;1.015)0.0062OR \> (\<1) means higher (lower) risk for higher % of change*Abbreviations*: *LNR* lymph node relapse, *CR PLN* completely resoluting pathological lymph node, *ΔDmax* change in largest axial diameter, *CI* confidence interval. \*Corrected for, pre-radiotherapy diameter, necrosis, calcifications and extra-capsular spread

Discussion {#Sec12}
==========

In an era where the role of planned neck dissection after CRT for locoregionally advanced head and neck cancer is diminishing \[[@CR8]--[@CR10]\], using prognostic information derived from the clinic and radiological examinations which can help predict treatment outcome and thereby the necessity of neck dissection, is gaining importance. The goal of this study is to situate the prognostic value of the location of pathological lymph nodes, as well as size change of pathological lymph nodes as evaluated on CT studies in the follow up after (C)RT. Data were conducted from a large patient cohort treated at our institute with (C)RT but without adjuvant neck dissection. As a result of this, data were correlated with clinical outcome, and not with pathology results from neck dissection. Therefore, we made sure to have sufficient follow-up for every patient. Multivariate analysis were done to correct for T stage, N stage, pre-RT diameter, necrosis, calcifications, HPV and ECS, since these factors are known to impact outcome \[[@CR11]--[@CR16]\].

To investigate the prognostic impact of the location of pathological lymph nodes, we analyzed the distribution of affected lymph node levels in our patient cohort, clustered adjacent levels and compared them to each other. As described for overall survival by Jones et al. in a large cohort of 947 patients, one would expect a worse prognosis with pathological involvement of higher numerical lymph node levels \[[@CR11]\]. We could establish a significant correlation between location and metastatic risk, without significant impact on the DFS. Involvement of level IV-V entails a higher risk to develop metastasis compared to level I-III. A similar, correlation was seen for involvement of level VI-VII compared to level IV-V; with a higher risk metastatic for involvement of level VI-VII. Presence of retropharyngeal lymph node metastasis (level VII), is known to be a risk factor for both regional and distant recurrence \[[@CR12]--[@CR15]\]. We could validate this result in our patient group for distant recurrence. Based on our data, and previous publications on this subject, we can state that involvement of higher numerical lymph node levels as evaluated on CT studies pretreatment entails a higher metastatic risk and represents more aggressive and advanced disease.

A second goal was to investigate the prognostic value of size change as evaluated on CT studies of pathological lymph nodes after (C)RT (radiotherapy with or without chemotherapy). Therefore we considered both volume and largest axial diameter change. The latter only at individual nodal level, given the fact that after treatment, determination of the largest axial diameter does not necessarily involve the same lymph node. Volume change was both at patient and individual nodal level of significant prognostic value. The less pronounced the volume reduction, the poorer the RC, DFS, MFS, OS and, at individual nodal level, and the more LNR. Due to linear relationships between volume change and outcome no clinically useful cut-off values could be selected.

At individual nodal level the analysis was done both in- and excluding completely responding lymph nodes. Including these lymph nodes yields a theoretical predictive prognostic effect of size change of pathological lymph nodes after treatment. Excluding them delivers us more clinically useful information about the predictive effect of the size change of a residual lymph node after treatment. In the clinic, disappeared pathological lymph nodes on post-treatment CT is considered obviously as a favorable prognostic sign. However, even after excluding disappearing pathological lymph nodes, the relationship between volume change and LNR remained significant. Our results are in concordance with the data published by Clavel et al. In patients with node-positive head and neck cancer, a significant effect of volume change after CRT was reported \[[@CR16]\]. In the light of adaptive RT, volume change of tumor and pathological lymph nodes during treatment has been studied extensively. However, data on the prognostic value of volume change after but also during RT are scarce. Mishra et al. failed to find a correlation between nodal volume change during (C)RT and neck control in 38 patients with locoregionally advanced head and neck cancer \[[@CR17]\]. Besides volume change, also the impact of change of largest nodal axial diameter on LNR was considered. Our data revealed, both in- and excluding completely responding pathological lymph nodes, a significant correlation between diameter change and outcome.

Because of this linear relationship no cut-off value could be selected. Clavel et al. described a negative predictive value (NPV) of 100% for a diameter decrease of \> 80%. Hamilton et al. and Ojiri et al. proposed a cutoff value of \>50% with NPV's of 94 and 100% respectively \[[@CR16], [@CR18], [@CR19]\]. An extensive discussion of the role of other imaging modalities of the neck after (C)RT such as ultrasound, PET-CT, and MRI is beyond the scope of this article, but each of those are believed to be useful in assessing response and the need for salvage neck dissection. Ultrasound (US), in combination with fine needle aspiration cytology (FNAC), is an inexpensive and readily available tool. Yom et al. described a NPV of 95% for US-FNAC in the non-irradiated neck \[[@CR20], [@CR21]\]. Diagnostic efficacy and in particular NPV of FNAC for residual or recurrent cervical lymph node metastasis is however significantly reduced after previous RT \[[@CR22]\]. Data on the role of post-treatment PET-CT are emerging rapidly, and results are promising. Loo et al. described a NPV of 100% for PET-CT obtained 3 months after completion of radiotherapy \[[@CR23]\]. This was further investigated in a multi-center study (PET-NECK), which recruited 564 patients with N2 or N3 head and neck cancer treated with CRT and randomized between routine ND and a wait and see approach if PET-CT 9-13 weeks after treatment shows no abnormal FDGuptake in the neck \[[@CR24]\]. This study reports similar results in patients who underwent PET-CT-guided surveillance and those who underwent planned neck dissection, but surveillance resulted in fewer operations and was more cost-effective. In the last few years advances in MRI, with development of diffusion weighted MR (DW-MRI) and dynamic contrast-enhanced MRI, have provided additional information. Recently, Vandecaveye et al. evaluated response after RT in 29 patients with DW-MRI at three weeks after completion of treatment. He reported a NPV of 96% for adenopathies per neck side, and a sensitivity of 78% of DW-MRI versus 67% for conventional MRI for detecting sub centimeter lymph node metastasis \[[@CR25]\].

This was a monocentric retrospective study, with its inherent limitations, analyzing a heterogeneous patient population over a large period of time. Nevertheless, the strength of this study lies in the large number of analyzed data and the fact that all measurements on the CT scans were performed by the same observer, with cooperation of both a radiation oncologist and radiologist specialized in head and neck cancer. Moreover, sufficient follow-up was carried out in a uniform manner.

Conclusions {#Sec13}
===========

Our data show the prognostic value of both location as well as size change of pathological lymph nodes after (C)RT in locoregionally advanced head and neck cancer. Involvement of level VI-VII entails the highest metastatic risk. In the follow-up of patients with lymph node involvement of level VI-VII, the threshold to do radiological examinations should be lower.

The less decrease of lymph node volume and largest axial diameter after treatment, the worse the outcome. Patients with less decrease in volume and largest axial diameter as evaluated on the post-treatment CT scan might therefore benefit from a more closer radiological and clinical follow-up of the neck.
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